Chronic heart failure is a serious, progressive pathology with a rising prevalence and a
mortality rate that has not improved in several decades. A new potential treatment strategy is …

Cardiac hypertrophy is a prerequisite for the development of heart failure. It currently affects
almost one million people in the UK. Few effective anti-hypertrophic agents with druggable …

Cardiac hypertrophy and heart failure are affecting almost one million people in the UK
alone. The available therapies of cardiac hypertrophy are for symptomatic treatment …

The plasma membrane calcium/calmodulin dependent ATPase (PMCA) ejects calcium from
the myocardium but its role in diastolic relaxation is minor. We have therefore been …

Cardiac bypertrophy is an important pathological process leading to heart failure (HF). The
identification of novel regulators of myocardial hypertrophy is key in understanding the …

We have recently shown that PMCA4 is involved in signaling in the heart by modulating the
function of nNOS, which is also calcium/calmodulin dependent, via a PDZ-domain …

In contrast to the classical premise that the sarcolemmal calcium pump (PMCA= Plasma
Membrane Ca2+/Calmodulin dependent ATPase) has a minor role in diastolic Ca2+ …

According to the European Society of Cardiology long-term out-patient registry, heart failure
with preserved ejection fraction (HFpEF) accounts for approximately 16% of heart failure …

Identification of novel regulators of cardiac hypertrophy is key in understanding the
mechanisms of heart failure. The plasma membrane calcium ATPase 4 (PMCA4) is a …

Adapted from:-VAM van de Schans; JFM Smits, WM Blankesteijn. The Wnt/Frizzled pathway
in cardiovascular development and disease: Friend or Foe. Eur J Pharmacol. 2008 May 13; …